Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 5.73B |
| Revenue (ttm) | 521.31M |
| Net Income (ttm) | -23.36M |
| Shares Out | 60.98M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 621,779 |
| Open | 93.06 |
| Previous Close | 92.48 |
| Day's Range | 93.06 - 94.22 |
| 52-Week Range | 40.00 - 109.28 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 119.00 (+26.62%) |
| Earnings Date | May 4, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $119.0, which is an increase of 26.62% from the latest price.
News
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Egetis Appoints Tiago Nunes as Chief Medical Officer
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Office...
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases.
Mirum Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Multiple pivotal clinical readouts and launches are expected over the next 18 months, with commercial guidance reaffirmed and significant market expansion planned. Market development, patient engagement, and synergistic infrastructure investments are central to growth, while business development remains active for rare disease assets.
Mirum Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
Focused on rare disease medicines, the company projects $630-650 million in annual revenue and anticipates four pivotal clinical readouts in the next 18 months. LIVMARLI and volixibat are each positioned as billion-dollar brands, with strong commercial growth and a robust pipeline supporting future expansion.
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus.
Mirum Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Strong commercial growth and robust late-stage pipeline drive revenue guidance of $630M–$650M for 2024. Multiple pivotal trial readouts are expected in 2024–2025, with LIVMARLI and volixibat each targeting $1B+ peak sales and new market expansions underway.
Mirum Pharmaceuticals Earnings Call Transcript: Q4 2025
Net product sales grew 55% year-over-year to $521 million in 2025, led by LIVMARLI and international expansion. Guidance for 2026 targets $630–$650 million in sales, with four pivotal clinical readouts expected and increased R&D investment, especially in brelovitug.
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
TORONTO--(BUSINESS WIRE)--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome.
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
TORONTO--(BUSINESS WIRE)--Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.
Top 3 Health Care Stocks That May Implode In Q1
As of Feb. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease.
Mirum Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong commercial growth and robust pipeline set the stage for a pivotal 18 months, with four major clinical readouts expected. Livmarli, Volixibat, and Brilovatug target significant rare disease markets, supported by durable revenue, expanding indications, and a well-financed outlook.
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum.
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its l...
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference.
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX.
Mirum Pharmaceuticals Transcript: M&A Announcement
The acquisition adds a late-stage, high-potential therapy for hepatitis delta to the rare disease portfolio, leveraging strong phase II data and regulatory designations. The $620M deal, plus milestones, is expected to drive significant synergies, expand market reach, and accelerate value creation.
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million
Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver disease to its portfolio.
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics,...
Mirum Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Three approved rare disease medicines are driving strong revenue and cash flow, with continued growth expected from both commercial products and a robust pipeline. The Fragile X program targets a billion-dollar market, while PSC and PBC trials advance with promising endpoints and manageable side effects.